RxDoctor Payments Data

William Coleman, MD

Procedural Dermatology · Metairie, LANPI 1104038439

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (49.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Merz North America, Inc. at 49.9% of the total. Reporting peaked in 2019 at $2,682 and has fallen 90.0% since, to $267 in 2025.

$5,237in general payments, 2019–2025

Across 73 payments — averaging $71.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merz North America, Inc.$3K
  • AbbVie$2K
  • Sanofi$266
  • E.r. Squibb & Sons, L.L.C.$178
  • Endo Pharmaceuticals Inc.$68
  • Amgen$60
  • plus $131 from 4 others
$1,060,756in research payments, 2019–2025

Across 80 payments — averaging $13,259 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$673K
  • Endo Pharmaceuticals Inc.$359K
  • Bausch Health US, LLC$29K

What the payments were for

  • Consulting fees$2,61050%
  • Travel & lodging$1,16422%
  • Food & beverage$1,45428%
  • Education$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few procedural dermatology providers in Louisianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$62,883
Medicare patients
202
Services billed
755

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab12$42,900
Doxycycline Hyclate166$3,188
Betamethasone Dipropionate60$2,880
Finasteride131$1,302
Fluocinonide35$1,284
Dutasteride44$1,261
Minoxidil80$1,056
Ketoconazole80$954
ValacyclovirValacyclovir Hcl36$941
Triamcinolone Acetonide129$855
Hydrocortisone63$702
Clobetasol Propionate19$522
Spironolactone34$518
Mupirocin50$426
Clotrimazole22$224

Paid to pharmacies, not to this prescriber.

Other procedural dermatology in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →